In vitro and in vivo cytotoxic effects of PRIMA-1 on hepatocellular carcinoma cells expressing mutant p 53 ser 249

Hong Shi, Jeremy M.R.Lambert, Agnes Hautefeuille, Vladimir J.N.Bykov, Klas G.Wiman, Pierre Hainaut and Claude Caron de Fromentel International Agency for Research on Cancer, 150 cours Albert Thomas, 69372 Lyon Cedex 08, France, Department of Oncology-Pathology, Cancer Center Karolinska, Karolinska Institutet, Karolinska University Hospital, 171 77 Stockholm, Sweden and Unité Institut National de la Santé et de la Recherche Médicale U590, Université Lyon-1, Centre Léon Bérard, 28 rue Laennec, 69373 Lyon Cedex 08, France

[1]  M. Olivier,et al.  Impact of mutant p53 functional properties on TP53 mutation patterns and tumor phenotype: lessons from recent developments in the IARC TP53 database , 2007, Human mutation.

[2]  L. Szekely,et al.  PRIMA-1MET induces nucleolar accumulation of mutant p53 and PML nuclear body-associated proteins , 2007, Oncogene.

[3]  Tao Wang,et al.  PRIMA-1 induces apoptosis by inhibiting JNK signaling but promoting the activation of Bax. , 2007, Biochemical and biophysical research communications.

[4]  J. Bruix,et al.  New aspects of diagnosis and therapy of hepatocellular carcinoma , 2006, Oncogene.

[5]  R. T. Ten Haken,et al.  Partial volume tolerance of the liver to radiation. , 2005, Seminars in radiation oncology.

[6]  U. Moll,et al.  In Vivo Mitochondrial p53 Translocation Triggers a Rapid First Wave of Cell Death in Response to DNA Damage That Can Precede p53 Target Gene Activation , 2004, Molecular and Cellular Biology.

[7]  M. Kew.  Synergistic interaction between aflatoxin B1 and hepatitis B virus in hepatocarcinogenesis , 2003, Liver international : official journal of the International Association for the Study of the Liver.

[8]  Galina Selivanova,et al.  Mutant p53-dependent growth suppression distinguishes PRIMA-1 from known anticancer drugs: a statistical analysis of information in the National Cancer Institute database. , 2002, Carcinogenesis.

[9]  Xin Lu,et al.  Live or let die: the cell's response to p53 , 2002, Nature Reviews Cancer.

[10]  C. Harris,et al.  The IARC TP53 database: New online mutation analysis and recommendations to users , 2002, Human mutation.

[11]  Jingwei Ji,et al.  Retinoblastoma and p53 tumor suppressor genes in human hepatoma cell lines , 1993, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[12]  P. Cerutti,et al.  Aflatoxin B1 induces the transversion of G-->T in codon 249 of the p53 tumor suppressor gene in human hepatocytes. , 1993, Proceedings of the National Academy of Sciences of the United States of America.

[13]  J. Wands,et al.  Selective G to T mutations of p53 gene in hepatocellular carcinoma from southern Africa , 1991, Nature.

[14]  H. Schägger.  Tricine–SDS-PAGE , 2006, Nature Protocols.

[15]  M. Ebara,et al.  Nonsurgical treatment of hepatocellular carcinoma in cirrhotic patients , 2004, World Journal of Surgery.

[16]  J. Ferlay,et al.  Globocan 2000 : cancer incidence, mortality and prevalence worldwide , 2001 .

[17]  R. Metcalf,et al.  Mutational hotspot in the p53 gene in human hepatocellular carcinomas. , 1991, Nature.

[18]  K. Isselbacher,et al.  Abnormal structure and expression of p 53 gene in human hepatocellular carcinoma ( hepatocarcinogenesis / recessive oncogene / gene expression ) , 2022 .